Barry Polisky

Title: Barry Polisky: Innovator in Nucleic Acid Ligands

Introduction

Barry Polisky is a notable inventor based in Boulder, CO (US). He has made significant contributions to the field of nucleic acid research, particularly in the development of high-affinity ligands that can discriminate between various target molecules.

Latest Patents

Polisky holds a patent for "High-affinity nucleic acid ligands that discriminate between." This invention describes methods for identifying and preparing nucleic acid ligands specifically for theophylline and caffeine. The patent includes a novel method termed counter-SELEX, which involves several steps to isolate nucleic acids with high affinity and selectivity for target molecules. The process includes preparing a candidate mixture of nucleic acids, partitioning those with increased affinity, and amplifying the nucleic acids to yield a mixture enriched for sequences with higher specificity for binding to the target molecule.

Career Highlights

Barry Polisky is associated with Nexstar Pharmaceuticals, Inc., where he continues to advance his research in nucleic acid technologies. His work has implications in various fields, including pharmaceuticals and biotechnology.

Collaborations

Polisky has collaborated with notable colleagues such as Robert Delmar Jenison and Larry M Gold, contributing to the advancement of nucleic acid research.

Conclusion

Barry Polisky's innovative work in the field of nucleic acid ligands showcases his expertise and dedication to scientific advancement. His contributions are paving the way for future developments in targeted molecular therapies.